The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

nuevolution.com

Founded Year

2001

Stage

Acq - P2P | Acquired

Total Raised

$33.8M

Valuation

$0000 

About Nuevolution

Nuevolution is a small molecule lead discovery company that has developed Chemetics, a hybrid of wet chemistry and molecular biology which represents fragment-based drug discovery technology. Chemetics enables rapid synthesis and DNA-tagging of chemically diverse drug-like small molecule compounds and the efficient screening of these, facilitating the identification of potent drug leads at unprecedented quantity, quality and speed compared to existing drug discovery technologies.

Nuevolution Headquarter Location

Ronnegade 8

Copenhagen, 2100,

Denmark

+45 7020 0987

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Nuevolution

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Nuevolution is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

838 items

Nuevolution Patents

Nuevolution has filed 30 patents.

The 3 most popular patent topics include:

  • Autoimmune diseases
  • Intracellular receptors
  • Transcription factors
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/11/2020

2/22/2022

Transcription factors, Intracellular receptors, Autoimmune diseases, Clusters of differentiation, Interleukins

Grant

Application Date

5/11/2020

Grant Date

2/22/2022

Title

Related Topics

Transcription factors, Intracellular receptors, Autoimmune diseases, Clusters of differentiation, Interleukins

Status

Grant

Latest Nuevolution News

Ultimovacs appoints Chief Business Officer

Nov 25, 2020

Ultimovacs appoints Chief Business Officer Search for content, post, videos Ton Berkien will join Ultimovacs’ management team as Chief Business Officer (CBO), effective December 1, 2020. Berkien will join Ultimovacs from his current position at Amgen as Director Global Business Development. At Ultimovacs, he will lead all business and corporate development efforts and continue to maintain and foster connections with leading biotechnology and pharmaceutical companies. “In the last months, Ultimovacs has strengthened its corporate and clinical development position having launched multiple mid-stage clinical trials and established a solid financial runway. As the clinical trials continue to advance, now is the right time to expand our management team and place a greater focus on our business development efforts,” commented Carlos de Sousa, Chief Executive Officer at Ultimovacs. “As a biopharmaceutical industry professional with an extensive international business development background, insights on corporate financing and years of experience in leading and executing business transactions, we welcome Ton to Ultimovacs’ management team and are enthusiastic to collaborate with him and continue to build value for the company, our shareholders and patients in need of novel therapeutic options.” Ton Berkien Ton Berkien joins Ultimovacs with over 15 years of experience in strategic business development and corporate finance in the biopharmaceutical industry, states Ultimovacs. His most recent position was at Amgen as Director Global Business Development – Transactions, a position he assumed in August 2019 following the acquisition of Nuevolution, a Danish small molecule development company, at which he led the commercial and business activities as Chief Business Officer. “During his tenure at Nuevolution, Berkien contributed to a number of corporate achievements including supporting the company’s successful listing onto Nasdaq OMX Stockholm, executing a program out-licensing deal with Almirall as well as drug discovery collaborations with Janssen Biotech and Amgen.” During his tenure at Nuevolution, Berkien contributed to a number of corporate achievements including supporting the company’s successful listing onto Nasdaq OMX Stockholm, executing a program out-licensing deal with Almirall as well as drug discovery collaborations with Janssen Biotech and Amgen. Prior to this, Berkien was acting Head of Corporate Development/M&A at Takeda/Nycomed, where he completed several M&A transactions in the United States, Europe and in various emerging growth markets such as China, Brazil, India and Colombia. Earlier in his career, Berkien also held senior manager positions at PricewaterhouseCoopers, Rijnconsult, KPMG and Gilde Investment Management. “Over the years, Ultimovacs’ lead therapeutic cancer vaccine program, UV1, has garnered interest from key opinion leaders, physicians and pharmaceutical companies based on its encouraging potential in a range of solid tumor cancers,” stated Ton Berkien, Chief Business Officer at Ultimovacs. “As Ultimovacs moves towards its next value inflection points, supported by a number of mid-stage clinical trials, together, we will build on the Company’s well-established scientific foundation to identify new, strategic opportunities and global partnerships. I greatly look forward to joining the accomplished management team and contributing to Ultimovacs’ ongoing growth and success as a biotechnology company developing novel immunotherapies against cancer.” Berkien is currently a board member of the Nordic Pharma Licensing Group. Before starting his career, he obtained a bachelor’s degree in Economics from the Saxion University of Applied Science in the Netherlands and an LSid from PwC/Harvard Business School/IMD. Berkien is a Dutch and Swedish citizen and is based in Sweden.

  • When was Nuevolution founded?

    Nuevolution was founded in 2001.

  • Where is Nuevolution's headquarters?

    Nuevolution's headquarters is located at Ronnegade 8, Copenhagen.

  • What is Nuevolution's latest funding round?

    Nuevolution's latest funding round is Acq - P2P.

  • How much did Nuevolution raise?

    Nuevolution raised a total of $33.8M.

  • Who are the investors of Nuevolution?

    Investors of Nuevolution include Amgen, SEB Venture Capital, Sunstone Capital, Industrifonden, Nordic Biotech and 5 more.

  • Who are Nuevolution's competitors?

    Competitors of Nuevolution include Carmot Therapeutics, FORMA Therapeutics, Quanterix, Prosarix, Kalexsyn and 15 more.

You May Also Like

M
MerLion Pharmaceuticals

MerLion Pharmaceuticals focuses on the discovery and development of drug candidates from natural sources. MerLion collaborates with leading pharmaceutical companies, biotechs and research institutes to identify and develop drug leads in a wide range of therapeutic areas.

A
AureoGen

AureoGen is a research-based biotech company with a focus on discovery and production of commercially and clinically important cyclic peptide-based drugs, through genetic engineering of cyclic peptide producing organisms (as an alternative to complex and expensive synthetic chemistry methods). AureoGen's business is centered on generating intellectual property, both through discovery of genes, molecules and organisms and through development of technology and engineered organisms.

A
AC PharmaChem

AC PharmaChem, Inc. is a fast growing company providing contract research and development services of medicinal chemistry, customer based organic synthesis of special chemical reagents, intermediates, reference compounds, and synthesis of focused libraries. The company's goal is to fully support the company's pharmaceutical and biotech partners to speed up and advance their drug discovery and innovation processes. At AC PharmaChem, the company have experienced medicinal and synthetic chemists utilizing synthetic techniques and instruments to provide cost efficient and on time delivery to meet the demands of the company's customers.

Oxford Drug Design Logo
Oxford Drug Design

Oxford Drug Design designs and develops small-molecule drugs against cancer, based on differentiated dual core competences. Its validated platform combines pioneering AI and machine learning methods with deep expertise in aminoacyl-tRNA synthetases, accelerating advances in the discovery and development of oncology therapeutics with novel mechanisms of action. It offers a its proprietary AI platform to pharmaceutical and biotechnology companies. Oxford Drug Design was founded in 2001 and is based in Oxford, England.

P
Proteopure

Proteomics is widely viewed as the cornerstone of future success in drug discovery and clinical diagnostics, but the complexity of protein molecules and their interactions requires new tools to find and understand biomarkers and protein functions. A critical step in the research process is to properly prepare the molecular sample before analysis can begin. Proteopure, Inc.'s technology is the foundation of a simple laboratory "kit" that fills unmet research needs.nProteopure developed and is now marketing sample protein preparation kits. In addition, Proteopure markets complementary products where there is overlapping customer synergy. These other products include a kit for membrane sample preparation, a kit for measuring protein concentration, fluorescent nanoclusters and beads for labeling proteins, and fluorescent tagged genes for measuring protein expression and location.

Silicos Logo
Silicos

silicos aims to empower virtual screening for in silico drug discovery

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.